AstraZeneca (LON:AZN) Stock Rating Reaffirmed by Shore Capital

Share on StockTwits

Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Wednesday morning, Digital Look reports.

Other analysts have also recently issued research reports about the company. UBS Group reaffirmed a sell rating and set a GBX 5,700 ($74.48) target price on shares of AstraZeneca in a research report on Tuesday, September 10th. Citigroup reaffirmed a buy rating and set a £100 ($130.67) target price (up previously from GBX 7,000 ($91.47)) on shares of AstraZeneca in a research report on Wednesday, September 11th. Goldman Sachs Group set a GBX 5,500 ($71.87) target price on AstraZeneca and gave the company a sell rating in a research report on Monday, September 2nd. Credit Suisse Group set a GBX 7,300 ($95.39) price objective on AstraZeneca and gave the company a buy rating in a report on Friday, July 26th. Finally, Bryan, Garnier & Co reiterated a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of GBX 7,050 ($92.12).

Shares of LON AZN opened at GBX 7,167 ($93.65) on Wednesday. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 144.48. The stock has a market capitalization of $94.02 billion and a PE ratio of 41.86. The stock’s fifty day simple moving average is GBX 7,191.39 and its two-hundred day simple moving average is GBX 6,415.44. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 7,583 ($99.09).

The firm also recently disclosed a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were issued a dividend of GBX 71.90 ($0.94) per share. The ex-dividend date was Thursday, August 8th. This represents a dividend yield of 1.07%. AstraZeneca’s dividend payout ratio is presently 1.28%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What is the Dividend Aristocrat Index?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Liberty Broadband Corp Series A  Sets New 52-Week High at $120.25
Liberty Broadband Corp Series A Sets New 52-Week High at $120.25
Perpetual Energy  Hits New 1-Year Low at $0.10
Perpetual Energy Hits New 1-Year Low at $0.10
FGL  Rating Lowered to Sell at Zacks Investment Research
FGL Rating Lowered to Sell at Zacks Investment Research
Armor Minerals  Hits New 1-Year Low at $0.34
Armor Minerals Hits New 1-Year Low at $0.34
Cubic  Releases FY20 Earnings Guidance
Cubic Releases FY20 Earnings Guidance
Biglari Holdings Inc  CEO Sardar Biglari Buys 100 Shares
Biglari Holdings Inc CEO Sardar Biglari Buys 100 Shares


 
© 2006-2019 Zolmax.